nifedipine has been researched along with Liver Cirrhosis in 17 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The pharmacokinetics and hemodynamic effects of nifedipine were studied in patients with liver cirrhosis and in age-matched healthy control subjects." | 9.06 | Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration. ( Breimer, DD; Danhof, M; Kleinbloesem, CH; van Brummelen, P; van Harten, J; Wilson, JP, 1986) |
| "A 43 year old man with HIV and HCV infection and liver cirrhosis developed fatal lactic acidosis within five days from starting nifedipine for arterial hypertension." | 7.75 | Fatal lactic acidosis precipitated by nifedipine in a patient treated with disulfiram and antiretrovirals. ( Mian, P; Moling, O; Pagani, L; Pristerà, R; Rimenti, G; Spoladore, G; Vedovelli, C, 2009) |
| "The influence of verapamil and nifedipine on hepatic indocyanine green kinetics was studied in 12 patients with HBsAg-positive cirrhosis and ascites." | 7.67 | The influence of verapamil and nifedipine on hepatic indocyanine green clearance in patients with HBsAg-positive cirrhosis and ascites. ( Chang, TT; Chiang, BN; Kong, CW; Lay, CS; Lee, FY; Lee, SD; Lin, HC; Lo, KJ; Tsai, YT; Yang, CM, 1988) |
| " After oral lidocaine, cirrhotic patients has a longer time to peak concentration (Tmax) and elimination half-life (t1/2), and a higher area under the curve (AUC)." | 6.68 | Pharmacokinetics of oral lidocaine and nifedipine in patients with liver cirrhosis. ( Klangwarnwong, D; Manorot, M; Praisontarangkul, OA; Tonsuwannont, W, 1996) |
| "Detailed examination of hemodynamics in patients with portal and pulmonary hypertension was performed upon acute drug tests and course administration of nitrosorbide++, corinfar and propranolol." | 5.07 | [Drug therapy of pulmonary and portal hypertension in liver cirrhosis]. ( Andreev, NG; Maev, IV; Vorob'ev, LP, 1991) |
| "The pharmacokinetics and hemodynamic effects of nifedipine were studied in patients with liver cirrhosis and in age-matched healthy control subjects." | 5.06 | Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration. ( Breimer, DD; Danhof, M; Kleinbloesem, CH; van Brummelen, P; van Harten, J; Wilson, JP, 1986) |
| " The pharmacokinetics of verapamil and of one of its metabolites, norverapamil, is changed after multiple oral dosing as has been described in patients with supraventricular tachyarrhythmias, angina pectoris or in patients with essential hypertension." | 3.76 | Pharmacokinetics of calcium channel blocking agents. ( Anderson, P, 1986) |
| "A 43 year old man with HIV and HCV infection and liver cirrhosis developed fatal lactic acidosis within five days from starting nifedipine for arterial hypertension." | 3.75 | Fatal lactic acidosis precipitated by nifedipine in a patient treated with disulfiram and antiretrovirals. ( Mian, P; Moling, O; Pagani, L; Pristerà, R; Rimenti, G; Spoladore, G; Vedovelli, C, 2009) |
| "Fourteen normotensive patients with liver disease (6 with cirrhosis and 8 with chronic hepatitis) and 7 healthy volunteers were given a single oral dose of nilvadipine 2 mg." | 3.68 | Elevated plasma nilvadipine concentration after single and chronic oral administration to patients with chronic liver disease. ( Fujishima, M; Ito, Y; Kikuchi, M; Kobayashi, K; Takata, Y; Tsukashima, A; Ueno, M; Yoshizumi, T, 1992) |
| "The influence of verapamil and nifedipine on hepatic indocyanine green kinetics was studied in 12 patients with HBsAg-positive cirrhosis and ascites." | 3.67 | The influence of verapamil and nifedipine on hepatic indocyanine green clearance in patients with HBsAg-positive cirrhosis and ascites. ( Chang, TT; Chiang, BN; Kong, CW; Lay, CS; Lee, FY; Lee, SD; Lin, HC; Lo, KJ; Tsai, YT; Yang, CM, 1988) |
| " After oral lidocaine, cirrhotic patients has a longer time to peak concentration (Tmax) and elimination half-life (t1/2), and a higher area under the curve (AUC)." | 2.68 | Pharmacokinetics of oral lidocaine and nifedipine in patients with liver cirrhosis. ( Klangwarnwong, D; Manorot, M; Praisontarangkul, OA; Tonsuwannont, W, 1996) |
| "Amlodipine, a dihydropyridine calcium antagonist, was synthesized in an attempt to develop a compound with a pharmacokinetic profile characteristic of this class, which would also have an increased oral bioavailability and extended clearance time." | 2.38 | The pharmacokinetic profile of amlodipine. ( Abernethy, DR, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (52.94) | 18.7374 |
| 1990's | 6 (35.29) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moling, O | 1 |
| Rimenti, G | 1 |
| Pristerà, R | 1 |
| Vedovelli, C | 1 |
| Pagani, L | 1 |
| Spoladore, G | 1 |
| Mian, P | 1 |
| Avagnina, P | 1 |
| Sansoè, G | 1 |
| Martini, M | 1 |
| Peretti, P | 1 |
| Tinivella, M | 1 |
| Molino, G | 1 |
| Li, D | 2 |
| Lu, H | 1 |
| Li, X | 2 |
| Quan, Q | 1 |
| Lu, W | 1 |
| Tonsuwannont, W | 1 |
| Praisontarangkul, OA | 1 |
| Manorot, M | 1 |
| Klangwarnwong, D | 1 |
| Neĭko, IeM | 1 |
| Mytnyk, ZM | 1 |
| Holovach, IIu | 1 |
| Takata, Y | 1 |
| Yoshizumi, T | 1 |
| Ito, Y | 1 |
| Kikuchi, M | 1 |
| Ueno, M | 1 |
| Tsukashima, A | 1 |
| Kobayashi, K | 1 |
| Fujishima, M | 1 |
| Vorob'ev, LP | 1 |
| Maev, IV | 1 |
| Andreev, NG | 1 |
| Abernethy, DR | 1 |
| Anderson, P | 1 |
| Macmathuna, P | 1 |
| O'Reilly, T | 1 |
| Kelleher, D | 1 |
| Barry, M | 1 |
| Feely, J | 1 |
| Keeling, PW | 1 |
| Miyamori, R | 1 |
| Marutani, K | 1 |
| Norisue, H | 1 |
| Fukui, T | 1 |
| Handa, S | 1 |
| Hosoda, Y | 1 |
| Lay, CS | 2 |
| Tsai, YT | 2 |
| Kong, CW | 2 |
| Lee, FY | 2 |
| Chang, TT | 1 |
| Lin, HC | 1 |
| Yang, CM | 1 |
| Lee, SD | 2 |
| Chiang, BN | 2 |
| Lo, KJ | 2 |
| van Harten, J | 2 |
| van Brummelen, P | 2 |
| Wilson, JH | 1 |
| Lodewijks, MT | 1 |
| Breimer, DD | 2 |
| Chen, KY | 1 |
| Kleinbloesem, CH | 1 |
| Wilson, JP | 1 |
| Danhof, M | 1 |
| Straumann, A | 1 |
| Gyr, K | 1 |
| Kiowski, W | 1 |
| Bruendler, H | 1 |
| Stalder, GA | 1 |
2 reviews available for nifedipine and Liver Cirrhosis
| Article | Year |
|---|---|
The pharmacokinetic profile of amlodipine.
Topics: Administration, Oral; Aging; Amlodipine; Angina Pectoris; Animals; Biological Availability; Calcium | 1989 |
Pharmacokinetics of calcium channel blocking agents.
Topics: Administration, Oral; Angina Pectoris; Atrial Fibrillation; Biological Availability; Cardiomegaly; C | 1986 |
6 trials available for nifedipine and Liver Cirrhosis
| Article | Year |
|---|---|
Calcium channel blockers in cirrhotic patients with portal hypertension.
Topics: Adolescent; Adult; Aged; Alkaloids; Animals; Benzylisoquinolines; Calcium Channel Blockers; Cinnariz | 1995 |
Pharmacokinetics of oral lidocaine and nifedipine in patients with liver cirrhosis.
Topics: Administration, Oral; Adult; Anesthetics; Cross-Over Studies; Female; Hemodynamics; Humans; Lidocain | 1996 |
[Drug therapy of pulmonary and portal hypertension in liver cirrhosis].
Topics: Adult; Aged; Antihypertensive Agents; Humans; Hypertension, Portal; Hypertension, Pulmonary; Isosorb | 1991 |
Pharmacokinetics of calcium channel blocking agents.
Topics: Administration, Oral; Angina Pectoris; Atrial Fibrillation; Biological Availability; Cardiomegaly; C | 1986 |
Lack of effects of nifedipine on hepatic hemodynamics in patients with HBsAg-positive cirrhosis.
Topics: Female; Hemodynamics; Hepatitis B Surface Antigens; Humans; Liver Circulation; Liver Cirrhosis; Male | 1987 |
Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration.
Topics: Absorption; Administration, Oral; Adult; Aged; Blood Pressure; Female; Half-Life; Heart Rate; Humans | 1986 |
10 other studies available for nifedipine and Liver Cirrhosis
| Article | Year |
|---|---|
Fatal lactic acidosis precipitated by nifedipine in a patient treated with disulfiram and antiretrovirals.
Topics: Acidosis, Lactic; Adult; Alcohol Deterrents; Alcoholism; Anti-Retroviral Agents; Antihypertensive Ag | 2009 |
Effects of nifedipine on functional liver plasma flow in normal subjects and in patients with cirrhosis.
Topics: Adult; Aged; Female; Humans; Liver Circulation; Liver Cirrhosis; Male; Middle Aged; Nifedipine; Refe | 1993 |
[Different therapeutic approaches for chronic diffuse liver lesions using ornicetil, lactulose, etimizol and corinfar].
Topics: Etimizol; Hepatic Encephalopathy; Hepatitis, Chronic; Humans; Lactulose; Liver Cirrhosis; Liver Dise | 2002 |
Elevated plasma nilvadipine concentration after single and chronic oral administration to patients with chronic liver disease.
Topics: Administration, Oral; Calcium Channel Blockers; Chronic Disease; Hemodynamics; Hepatitis; Humans; Li | 1992 |
[Use of calcium-channel blockers in cirrhotic patients with portal hypertension].
Topics: Adolescent; Adult; Aged; Alkaloids; Animals; Benzylisoquinolines; Calcium Channel Blockers; Cinnariz | 1990 |
The effect of calcium channel blockade with nifedipine on splanchnic and systemic haemodynamics in cirrhosis.
Topics: Hemodynamics; Humans; Hypertension, Portal; Liver Cirrhosis; Nifedipine; Splanchnic Circulation | 1987 |
[A case of pulmonary hypertension associated with liver cirrhosis and hepatoma].
Topics: Carcinoma, Hepatocellular; Humans; Hypertension, Pulmonary; Liver Cirrhosis; Liver Neoplasms; Male; | 1985 |
The influence of verapamil and nifedipine on hepatic indocyanine green clearance in patients with HBsAg-positive cirrhosis and ascites.
Topics: Aged; Ascites; Female; Hepatitis B Surface Antigens; Humans; Indocyanine Green; Liver; Liver Cirrhos | 1988 |
Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration.
Topics: Administration, Oral; Adolescent; Adult; Aged; Blood Pressure; Calcium Channel Blockers; Female; Hal | 1988 |
Hemodynamic effects of nifedipine on hepatic venous pressure gradient in patients with portal hypertension.
Topics: Adult; Aged; Female; Hemodynamics; Hepatic Veins; Humans; Hypertension, Portal; Liver Cirrhosis; Mal | 1986 |